Several breast cancer characteristics at diagnosis that are associated with increased risk of recurrence were more frequent in the Italian MetBreCS trial, such as grading, hormone receptor, and HER2 status were more common in the MetBreCS trial as this trial was designed for breast cancer survivors at high risk of recurrence. Here, NR4A1 is linked to breast cancer.